XBiotech Inc. (NASDAQ:XBIT) Short Interest Up 452.0% in July

XBiotech Inc. (NASDAQ:XBIT) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 516,100 shares, agrowthof452.0% from the June 30th total of 93,500 shares. Approximately2.7% of the company’s shares are short sold. Based on an average trading volume of 93,700 shares, the short-interest ratio is presently 5.5 days. Based on an average trading volume of 93,700 shares, the short-interest ratio is presently 5.5 days. Approximately2.7% of the company’s shares are short sold.

XBiotech Stock Performance

NASDAQ XBIT opened at $2.85 on Friday. The firm’s 50 day moving average price is $2.88 and its 200-day moving average price is $3.09. XBiotech has a 52-week low of $2.50 and a 52-week high of $8.32. The company has a market cap of $86.90 million, a PE ratio of -2.21 and a beta of 0.97.

XBiotech (NASDAQ:XBIT) last released its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On XBiotech

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Northern Trust Corp boosted its stake in shares of XBiotech by 15.2% during the fourth quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company’s stock valued at $835,000 after purchasing an additional 27,909 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of XBiotech by 15.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 8,918 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of XBiotech during the second quarter valued at approximately $142,000. Deutsche Bank AG bought a new position in shares of XBiotech during the fourth quarter valued at approximately $120,000. Finally, Barclays PLC boosted its stake in shares of XBiotech by 13.9% during the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 3,661 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.